Extended Data Table 1 Primary outcome of treatment-emergent adverse events by system organ class and preferred term at 2 years

From: Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results